Whilst long established in breast cancer, the highly effective option of aromatase inhibitors as adjuvant maintenance treatment has never been thoroughly examined for its use in ovarian cancer due to the disinterest of pharmacological industries. This evidence concerns the gene CYP19A1 and ovarian cancer.